Abstract: The disclosure relates to a method of treating or preventing Myasthenia Gravis (MG) in a human in need thereof using an anti-FcRn antibody or antigen binding fragment thereof. In particular, the method provides suitable dosage regimens for such treatment.

Abstract: The disclosure relates to a method of treating or preventing immune (idiopathic) thrombocytopenic purpura (ITP) in a human in need thereof, the method comprising administering to the human in the range of 1 to 5 doses of an anti-FcRn antibody or antigen binding fragment thereof over a treatment period of 1 to 12 weeks, wherein the aggregate dose in the treatment period is in the range of 1 to 30 mg per kg.

Abstract: A method is described that improves the transport properties of albumin produced on an industrial scale, wherein the albumin is mixed, during the production process, with substances that saturate the binding points on the albumin. Furthermore, pasteurized and then octanoate-reduced human albumin and therapeutic uses of such albumin is described. Such albumin may be useful in detoxifying human plasma, e.g. for the intravenous treatment of acute or chronic liver diseases, and as a dialysate in extracorporeal liver dialysis.

Abstract: A method is described that improves the transport properties of albumin produced on an industrial scale, wherein the albumin is mixed, during the production process, with substances that saturate the binding points on the albumin. Furthermore, pasteurized and then octanoate-reduced human albumin and therapeutic uses of such albumin is described. Such albumin may be useful in detoxifying human plasma, e.g. for the intravenous treatment of acute or chronic liver diseases, and as a dialysate in extracorporeal liver dialysis.

Abstract: The invention relates to the improvement of the transport properties of albumin which is produced on an industrial scale, e.g. via the Cohn process or by means of recombinant processes, and is mixed, during the production process, with substances that saturate the binding points on the albumin and thus affect the binding properties and transport properties of the final product. A special embodiment of the invention relates to pasteurized and then octanoate-reduced human albumin for therapeutic use, especially in a detoxification treatment of human plasma, e.g. for the intravenous treatment of acute or chronic liver diseases, and as a dialysate in extracorporeal liver dialysis with albumin in the molecular adsorbent recirculating system (MARS) or in single-pass dialysis.